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members, and guests, thank you for the privilege and being asked
to begin the discussion on this paper. The authors have queried the
NSQIP database over a recent 5-year interval and analyzed over
5300 tibial bypasses, assessing 30-day patency rates by conduit.
Nearly 75% of these used GSV and the remainder, various alterna-
tive conduits. This study does not attempt to address long-term
patency for which some of such venous adjuncts like the Taylor
patch or Miller cuff were theoretically developed to improve.
And though the authors conﬁrm the ﬁndings of others as to overall
inferior patency in African Americans and women, it does not give
any added insight as to why this is so.
However, the authors have succeeded in giving us a useful
snapshot of these early graft results that addresses a very real clin-
ical issue. Not surprisingly, the 30-day prosthetic patency and
composite graft patency were signiﬁcantly inferior to autogenous
great saphenous vein. Surprisingly, however, this difference at 30
days was only about 3% for prosthetic alone, and there was no
signiﬁcant difference for prosthetic with vein patch. Thus, they
conclude that while composite grafts are clearly inferior, a vein
patch at the distal prosthetic anastomosis may add to early graft
patency–even rivaling that for saphenous vein.
Like many large database analyses, the devil is in the details.
My ﬁrst question for the authors is could you clarify the prosthetic
graft type (heparin-bonded or -hooded) and antiplatelet and anti-
coagulation regimens that might contribute to such good early
prosthetic results?
Also of interest is that the composite spliced vein and arm vein
patencies were comparable to GSV at 30 days. My personal expe-
rience is that more than one splice becomes counterproductive.
Could the authors tell us how many splices are worthwhileeonly
one? Or, two or three–before beginning to approximate the
patency of a prosthetic?
Given the 30-40% increase in operative time with spliced or
arm vein compared to a prosthetic and vein patch, with no early
patency advantage, can the authors answer their own question:
when is it ever worthwhile to go to this extra effort?I enjoyed the presentation and once again thank the Associa-
tion for the privilege of opening the discussion.
Dr Bao-Ngoc Nguyen. Thank you, Dr Robison. I am going
to try to answer your questions in order. The ﬁrst question
regarding the kind of prosthetic conduits and the antiplatelet/anti-
coagulation regimens, unfortunately, one of the limitations of
using the NSQIP database, as you pointed out, is that it records
only 30-day outcomes. We queried the cases based on CPT codes,
and our current CPT codes only identify prosthetic conduits as
a whole without differentiating the different types of prosthetic
graft available. The use of antiplatelet or anticoagulation medica-
tions was also not recorded in the NSQIP database.
The second question regarding splicing multiple segments of
autologous veins and your observation that splicing more than
two pieces is no longer beneﬁcial, I could go back to the database
and subdivide spliced veins into two different groups of two versus
three or more segments because the CPT codes allow us to do
that. However, the number of each group would be lower and
the power of analysis might be lost.
The third question regarding how time-consuming splicing
vein is and whether using prosthetic with distal adjuvant could
be much quicker with potential equivalent results, this is a very
good question and it was the original question we raised in this
paper. In certain ways, 30-day graft patency is a prerequisite for
long-term patency. If the bypass is not patent at 30 days, the
chance that it is patent long-term is minimal. Therefore, the one
deﬁnitive answer suggested by the data of this paper is that
composite and prosthetic alone should not be used because the
30-day patency was signiﬁcantly worse than other conduits.
Unfortunately, we cannot answer deﬁnitively about splicing
veins versus prosthetic with distal adjuvant because they seem to
be equivalent at 30 days, yet the long-term data are lacking. We
think that the beneﬁt of distal venous adjuvant derives from atten-
uating myointimal hyperplasia, which is the main cause of graft
failure beyond 6 months. Since we don’t have this data beyond
30 days, the question of whether to use splicing veins or prosthetic
conduits with distal adjuvant remains unanswered.
